Noncanonical glycogen metabolism and hepatocellular carcinoma

NIH RePORTER · NIH · P20 · $222,001 · view on reporter.nih.gov ↗

Abstract

Hepatocellular carcinoma is one of the most common and deadliest cancers in the world due to limited treatment options and lack of knowledge of effective molecular targets. Thus, there is an urgent need to identify more effective therapeutic strategies to treat hepatocellular carcinoma. Emerging evidence has shown that canonical routes of glycogen metabolism are linked to hepatocellular carcinoma initiation and progression. However, the role of non-canonical routes of glycogen metabolism in hepatocellular carcinoma remains enigmatic. The objective of this proposal is the define how targeting non-canonical routes of glycogen metabolism modifies hepatocellular carcinoma in various mouse models. Completion of the proposed studies will greatly advance our understanding of glycogen metabolism in the context of hepatocellular carcinoma and potentially reveal a novel alternative approach to treat hepatocellular carcinoma, for which there are currently limited treatment options for.

Key facts

NIH application ID
10736748
Project number
5P20GM135002-03
Recipient
LSU PENNINGTON BIOMEDICAL RESEARCH CTR
Principal Investigator
Timothy D. Heden
Activity code
P20
Funding institute
NIH
Fiscal year
2022
Award amount
$222,001
Award type
5
Project period
2022-11-15 → 2025-01-31